SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention amid volatile natural-gas futures, with traders weighing winter weather forecasts, storage reports and pipeline or LNG supply disruptions. Bulls see potential for weather-driven demand and supply tightness, while bears point to mild-weather expectations, ample production and the leveraged funds compounding and futures-roll risks.

ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is drawing attention as traders bet on weaker natural-gas prices, pointing to large storage injections, ample production, and expectations of mild weather or a warm winter. Others see potential support from heat-driven demand, LNG or pipeline disruptions, and tighter storage, leaving the discussion focused on volatile swings and the risks of holding a leveraged ETF.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus oncology pipeline: FDA clearance to expand its recurrent glioblastoma trial and upcoming GBM data, alongside completion of enrollment in its pancreatic cancer study. Traders are broadly bullish on the approaching clinical milestones, while some point to price consolidation and note that early results still need validation in larger cohorts.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Reports that the U.S. would not strike Iran have fueled hopes for a relief bounce, but traders remain divided over whether the conflict and elevated oil prices still threaten markets. Attention is also on a packed week of Fed decisions, major tech earnings, and GDP and inflation data, adding to expectations for volatility.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention as traders watch upcoming earnings and its role supplying indium-phosphide substrates for AI data-center optics. Bulls point to AI-driven demand and growth potential, while bears focus on the stocks sharp volatility, rich valuation, and China-related supply risks.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

EWZ is drawing attention around Brazils presidential runoff, with traders positioning for a possible Flvio Bolsonaro win that they view as more market-friendly. Optimistic call activity and the ETFs sharp run-up are countered by downside hedges and concerns that the result may already be priced in, keeping the focus on election-driven volatility.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys run toward record highs and anticipation of its quarterly report are driving attention, with traders expecting continued Mounjaro and Zepbound demand to support results and guidance. The outlook is broadly bullish, though some traders question the stocks valuation and flag intensifying competition in oral obesity drugs.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Fears of renewed U.S.-Iran conflict and disruption to oil flows around the Strait of Hormuz and Saudi infrastructure are driving crude higher and lifting USO. Traders are split between expecting the supply-risk rally to continue and betting on a sharp reversal if tensions ease or a deal emerges; some also warn that high oil could fuel inflation and pressure equities.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Positive prostate-cancer trial updates, including data on J&Js investigational JNJ-6143 and apalutamide, are driving attention. Traders are broadly optimistic about the oncology news, while debating whether it can sustain a share-price recovery or is already reflected in the stock.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio is drawing attention ahead of its upcoming earnings report, with traders watching whether growth and demand can sustain a recent rebound. The discussion is split between bullish pre-earnings momentum and caution that reported growth includes carrier pass-through fees, making organic growth and expansion excluding those fees important measures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus ConferencePR NewswireSAN JOSE, Calif., Oct. 13, 2026Dr. Jose...

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical TrialPR NewswireSAN JOSE, Calif., Oct. 5, 2026First patient in current dose...

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical TrialPR NewswireSAN JOSE, Calif., Oct. 1, 2026Multiple Patients...

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040PR NewswireSAN JOSE, Calif., Sept. 21, 2026...

Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board

Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory BoardPR NewswireSAN JOSE, Calif., Sept. 16, 2026 SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.("Anixa...

Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV

Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV PR Newswire SAN JOSE, Calif., Sept. 9...

Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026

Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 PR Newswire SAN JOSE, Calif., Sept. 3, 2026 Presentation to highlight Anixa's clinical progress and...

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian...

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SAN JOSE, Calif., Aug. 18, 2026 Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose...

Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know

Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The Other segment refers to its legacy operations, including patent licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Anixa Biosciences Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.99
Prev Close	$2.78
Open	$2.80
Dividend Yield	0.00%
50-Day Moving Average	$3.00
Beta	1.18
Avg. Volume	378,775.14
PE Ratio	-9.65

52-Week High	$5.46
52-Week Low	$2.32
Market Capitalization	$103.94M
EPS (Annual)	-$0.3367
Price to Book	7.15
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANIX Fundamentals